T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

NCT03049449 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

NIH

Sponsor class

Conditions

Lymphoma, Large-Cell, Anaplastic
Enteropathy-Associated T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Extranodal NK-T-Cell
Lymphoma, T-Cell, Peripheral

Interventions

BIOLOGICAL: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)